Page last updated: 2024-11-12

bms 477118

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11243969
CHEMBL ID385517
CHEBI ID71272
SCHEMBL ID17168
SCHEMBL ID20243458
MeSH IDM0492354

Synonyms (65)

Synonym
AC-6008
HY-10285
(1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2,2,2-trifluoroacetic acid
bdbm11542
bms-477118
(s)-3-hydroxyadamantylglycine-l-cis-4,5-methanoprolinenitrile tfa salt
onglyza
opc-262
bdbm50225074
(1s,6s)-2-(2-adamantan-1-yl-2-amino-acetyl)-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile
(1s,3s,5s)-2-[(s)-2-amino-2-(3-hydroxy-adamantan-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile
DB06335
saxagliptin anhydrous
(1s,3s,5s)-2-((2s)-amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile
chebi:71272 ,
CHEMBL385517 ,
D08996
saxagliptin (usan/inn)
bms 477118
HMS3264P11
EX-7795
2-azabicyclo(3.1.0)hexane-3-carbonitrile, 2-((2s)-amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl) , (1s,3s,5s)-
8i7io46ivq ,
hsdb 8199
opc 262
unii-8i7io46ivq
saxagliptin [inn]
tox21_112908
cas-361442-04-8
dtxcid3028506
dtxsid7048580 ,
pharmakon1600-01502500
nsc760407
2-azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1s,3s,5s)-
AM20090693
(1s,3s,5s)-2-((2s)-amino(3-hydroxytricyclo(3.3.1.1(sup 3,7))dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile
saxagliptin [who-dd]
2-azabicyclo(3.1.0)hexane-3-carbonitrile, 2-((2s)-amino(3-hydroxytricyclo(3.3.1.1(sup 3,7))dec-1-yl)acetyl), (1s,3s,5s)-
saxagliptin [mi]
CS-0650
S1540
AKOS015896547
(1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
gtpl6316
(1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
CCG-213084
MLS006011223
smr004702984
SCHEMBL17168
saxagliptine
QGJUIPDUBHWZPV-SGTAVMJGSA-N
(1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-1-oxoethyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
AB01562984_01
AB01562984_02
Z2235802036
NCGC00242597-02
Q3121121
saxagliptin (bms-477118,onglyza)
SCHEMBL20243458
2-azabicyclo[3.1.0]hexane-3-carbonitrile,2-[(2s)-amino(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1s,3s,5s)-
BRD-A81513827-001-03-6
(1s,3s,5s)-2-((2s)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile
CCG-267647
NCGC00242597-10
EN300-761487

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" With our continuous interest in developing AM2-S31N inhibitors as oral influenza antivirals, we report here the progress of optimizing the in vitro pharmacokinetic (PK) properties of AM2-S31N inhibitors."( In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.
Hau, RK; Hu, Y; Ma, C; Musharrafieh, R; Wang, J; Wang, Y; Xu, S; Zhang, Y, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" Taken together, the excretion data suggest that saxagliptin was well absorbed and was subsequently cleared by both urinary excretion and metabolism; the formation of M2 was the major metabolic pathway."( Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Barros, A; Bonacorsi, SJ; Boulton, DW; Cao, K; Christopher, LJ; Humphreys, WG; Iyer, RA; Su, H; Wang, L, 2012
)
0.38
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
hypoglycemic agentA drug which lowers the blood glucose level.
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitorAn EC 3.4.14.* (dipeptidyl- and tripeptidyl-peptidases) inhibitor that specifically inhibits dipeptidyl peptidase-4 (EC 3.4.14.5).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
adamantanesCompounds containing an adamantane skeleton.
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
azabicycloalkane
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency23.41240.006038.004119,952.5996AID1159521; AID1159523
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency16.78550.001530.607315,848.9004AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency23.91450.000229.305416,493.5996AID743069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)100.00000.00011.753610.0000AID240740
Dipeptidyl peptidase 4Homo sapiens (human)IC50 (µMol)0.01980.00010.444410.0000AID1069728; AID1127772; AID1917944; AID427677; AID484489; AID611365; AID749996
Dipeptidyl peptidase 4Homo sapiens (human)Ki0.00060.00000.34142.2000AID1796747; AID238571; AID273290; AID302901; AID393692; AID429380
Prolyl endopeptidase FAPHomo sapiens (human)IC50 (µMol)860.50000.01201.15895.8300AID1663821; AID1663823
Dipeptidyl peptidase 8Homo sapiens (human)IC50 (µMol)0.24200.00192.653210.0000AID484490; AID688693
Dipeptidyl peptidase 8Homo sapiens (human)Ki0.13000.00150.46241.3420AID273291
Dipeptidyl peptidase 9Homo sapiens (human)IC50 (µMol)0.10200.00011.420710.0000AID484491; AID688690
Dipeptidyl peptidase 9Homo sapiens (human)Ki0.07100.00050.20621.3420AID273292
Dipeptidyl peptidase 2Homo sapiens (human)IC50 (µMol)30.00000.00020.93166.6000AID688688
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dipeptidyl peptidase 4Homo sapiens (human)Kd0.00810.00000.00800.0285AID1631907; AID1631913
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)Km81.70001.93005.90608.7000AID1218735
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (54)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A5Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A5Homo sapiens (human)
steroid metabolic processCytochrome P450 3A5Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A5Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A5Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A5Homo sapiens (human)
retinol metabolic processCytochrome P450 3A5Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A5Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A5Homo sapiens (human)
oxidative demethylationCytochrome P450 3A5Homo sapiens (human)
behavioral fear responseDipeptidyl peptidase 4Homo sapiens (human)
response to hypoxiaDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 4Homo sapiens (human)
cell adhesionDipeptidyl peptidase 4Homo sapiens (human)
positive regulation of cell population proliferationDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of extracellular matrix disassemblyDipeptidyl peptidase 4Homo sapiens (human)
peptide hormone processingDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellDipeptidyl peptidase 4Homo sapiens (human)
T cell costimulationDipeptidyl peptidase 4Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrinDipeptidyl peptidase 4Homo sapiens (human)
locomotory exploration behaviorDipeptidyl peptidase 4Homo sapiens (human)
psychomotor behaviorDipeptidyl peptidase 4Homo sapiens (human)
T cell activationDipeptidyl peptidase 4Homo sapiens (human)
endothelial cell migrationDipeptidyl peptidase 4Homo sapiens (human)
symbiont entry into host cellDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated virion attachment to host cellDipeptidyl peptidase 4Homo sapiens (human)
negative chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
membrane fusionDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of neutrophil chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
glucagon processingDipeptidyl peptidase 4Homo sapiens (human)
angiogenesisProlyl endopeptidase FAPHomo sapiens (human)
proteolysisProlyl endopeptidase FAPHomo sapiens (human)
cell adhesionProlyl endopeptidase FAPHomo sapiens (human)
regulation of collagen catabolic processProlyl endopeptidase FAPHomo sapiens (human)
negative regulation of extracellular matrix disassemblyProlyl endopeptidase FAPHomo sapiens (human)
endothelial cell migrationProlyl endopeptidase FAPHomo sapiens (human)
proteolysis involved in protein catabolic processProlyl endopeptidase FAPHomo sapiens (human)
regulation of cell cycleProlyl endopeptidase FAPHomo sapiens (human)
regulation of fibrinolysisProlyl endopeptidase FAPHomo sapiens (human)
negative regulation of cell proliferation involved in contact inhibitionProlyl endopeptidase FAPHomo sapiens (human)
melanocyte proliferationProlyl endopeptidase FAPHomo sapiens (human)
positive regulation of execution phase of apoptosisProlyl endopeptidase FAPHomo sapiens (human)
melanocyte apoptotic processProlyl endopeptidase FAPHomo sapiens (human)
negative regulation of extracellular matrix organizationProlyl endopeptidase FAPHomo sapiens (human)
proteolysisDipeptidyl peptidase 8Homo sapiens (human)
apoptotic processDipeptidyl peptidase 8Homo sapiens (human)
immune responseDipeptidyl peptidase 8Homo sapiens (human)
negative regulation of programmed cell deathDipeptidyl peptidase 8Homo sapiens (human)
pyroptosisDipeptidyl peptidase 9Homo sapiens (human)
negative regulation of programmed cell deathDipeptidyl peptidase 9Homo sapiens (human)
proteolysisDipeptidyl peptidase 9Homo sapiens (human)
proteolysisDipeptidyl peptidase 2Homo sapiens (human)
lysosomal protein catabolic processDipeptidyl peptidase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (37)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 3A5Homo sapiens (human)
iron ion bindingCytochrome P450 3A5Homo sapiens (human)
protein bindingCytochrome P450 3A5Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A5Homo sapiens (human)
oxygen bindingCytochrome P450 3A5Homo sapiens (human)
heme bindingCytochrome P450 3A5Homo sapiens (human)
aromatase activityCytochrome P450 3A5Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
virus receptor activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
signaling receptor bindingDipeptidyl peptidase 4Homo sapiens (human)
protein bindingDipeptidyl peptidase 4Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 4Homo sapiens (human)
protein homodimerization activityDipeptidyl peptidase 4Homo sapiens (human)
chemorepellent activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingProlyl endopeptidase FAPHomo sapiens (human)
endopeptidase activityProlyl endopeptidase FAPHomo sapiens (human)
serine-type endopeptidase activityProlyl endopeptidase FAPHomo sapiens (human)
integrin bindingProlyl endopeptidase FAPHomo sapiens (human)
protein bindingProlyl endopeptidase FAPHomo sapiens (human)
peptidase activityProlyl endopeptidase FAPHomo sapiens (human)
serine-type peptidase activityProlyl endopeptidase FAPHomo sapiens (human)
dipeptidyl-peptidase activityProlyl endopeptidase FAPHomo sapiens (human)
identical protein bindingProlyl endopeptidase FAPHomo sapiens (human)
protein homodimerization activityProlyl endopeptidase FAPHomo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 8Homo sapiens (human)
protein bindingDipeptidyl peptidase 8Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 8Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 8Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 9Homo sapiens (human)
protein bindingDipeptidyl peptidase 9Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 9Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 9Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 9Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 2Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 2Homo sapiens (human)
serine-type exopeptidase activityDipeptidyl peptidase 2Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A5Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A5Homo sapiens (human)
extracellular regionDipeptidyl peptidase 4Homo sapiens (human)
lysosomal membraneDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
focal adhesionDipeptidyl peptidase 4Homo sapiens (human)
cell surfaceDipeptidyl peptidase 4Homo sapiens (human)
membraneDipeptidyl peptidase 4Homo sapiens (human)
apical plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
lamellipodiumDipeptidyl peptidase 4Homo sapiens (human)
endocytic vesicleDipeptidyl peptidase 4Homo sapiens (human)
lamellipodium membraneDipeptidyl peptidase 4Homo sapiens (human)
membrane raftDipeptidyl peptidase 4Homo sapiens (human)
intercellular canaliculusDipeptidyl peptidase 4Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
extracellular spaceProlyl endopeptidase FAPHomo sapiens (human)
cytoplasmProlyl endopeptidase FAPHomo sapiens (human)
plasma membraneProlyl endopeptidase FAPHomo sapiens (human)
focal adhesionProlyl endopeptidase FAPHomo sapiens (human)
cell surfaceProlyl endopeptidase FAPHomo sapiens (human)
membraneProlyl endopeptidase FAPHomo sapiens (human)
lamellipodiumProlyl endopeptidase FAPHomo sapiens (human)
lamellipodium membraneProlyl endopeptidase FAPHomo sapiens (human)
ruffle membraneProlyl endopeptidase FAPHomo sapiens (human)
apical part of cellProlyl endopeptidase FAPHomo sapiens (human)
basal part of cellProlyl endopeptidase FAPHomo sapiens (human)
peptidase complexProlyl endopeptidase FAPHomo sapiens (human)
plasma membraneProlyl endopeptidase FAPHomo sapiens (human)
cytoplasmDipeptidyl peptidase 8Homo sapiens (human)
cytoplasmDipeptidyl peptidase 8Homo sapiens (human)
cytosolDipeptidyl peptidase 8Homo sapiens (human)
cytosolDipeptidyl peptidase 9Homo sapiens (human)
nucleusDipeptidyl peptidase 9Homo sapiens (human)
cytosolDipeptidyl peptidase 9Homo sapiens (human)
microtubuleDipeptidyl peptidase 9Homo sapiens (human)
cell leading edgeDipeptidyl peptidase 9Homo sapiens (human)
extracellular regionDipeptidyl peptidase 2Homo sapiens (human)
Golgi apparatusDipeptidyl peptidase 2Homo sapiens (human)
azurophil granule lumenDipeptidyl peptidase 2Homo sapiens (human)
intracellular membrane-bounded organelleDipeptidyl peptidase 2Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 2Homo sapiens (human)
vesicleDipeptidyl peptidase 2Homo sapiens (human)
vesicleDipeptidyl peptidase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (122)

Assay IDTitleYearJournalArticle
AID1218749Drug metabolism in human assessed as parent compound level in feces at 50 mg, po after up to 168 hrs by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1487389Inhibition of membrane-bound DPP-4 (unknown origin) assessed as association rate constant2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1218737Drug metabolism in assessed as ratio of Vmax to Km for human CYP3A4-mediated formation of 5-hydroxy saxagliptin Michaelis-Menten kinetic analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218794Inhibition of CYP2B6 in human liver microsomes assessed as bupropion hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218758Oral bioavailability in dog2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218736Drug metabolism in assessed as human CYP3A5-mediated formation of 5-hydroxy saxagliptin Michaelis-Menten kinetic analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218784Inhibition of CYP2B6 in human liver microsomes assessed as bupropion hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1487387Inhibition of solubilized DPP-4 (unknown origin) assessed as dissociation rate constant2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID393692Inhibition of human DPP42009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1218782Inhibition of CYP1A2 in human liver microsomes assessed as phenacetin O-deethylation after 3 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1663821Inhibition of FAP in human U87MG cells using Suc-Gly-Pro-AMC as substrate by fluorescence based assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
A cell-based fluorescent assay for FAP inhibitor discovery.
AID1487388Inhibition of solubilized DPP-4 (unknown origin) assessed as residence time2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1218786Inhibition of CYP2C9 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID688687Selectivity ratio of IC50 for DPP8 to IC50 for human DPP42012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
AID1218734Drug metabolism in human liver microsomes assessed as formation of 5-hydroxy saxagliptin Michaelis-Menten kinetic analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID240411Effective dose for inhibition of Dipeptidyl peptidase IV in prediabetic rat model after 2 hr2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
AID1218790Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 3 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218754Drug metabolism assessed as human CYP3A4-mediated 5-hydroxy saxagliptin formation at 10 uM after 30 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID243823Ex vivo Dipeptidyl peptidase IV inhibition in rat plasma after 4 hr 4 umol/kg peroral dose2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
AID1218747Drug metabolism in human assessed as parent compound level in urine at 50 mg, po after up to 168 hrs by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID240416Effective dose for inhibition of Dipeptidyl peptidase IV in prediabetic rat model after 0.5 hr2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
AID1487386Inhibition of solubilized DPP-4 (unknown origin) assessed as association rate constant2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1218774AUC (infinity) in human at 50 mg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218795Inhibition of CYP2C8 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1631912Inhibition of human DPP4 assessed as dissociation rate constant using gly-pro-pNA as substrate preincubated for 30 mins followed by substrate addition by fluorescence plate reader analysis2016Journal of medicinal chemistry, Aug-25, Volume: 59, Issue:16
Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure.
AID1218802Cytotoxicity against human hepatocytes assessed as change in morphological integrity up to 25 uM2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID273290Inhibition of human DPP4 expressed in Caco-2 cells2006Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the tr
AID1218760Drug excretion in human urine at 50 mg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218751Drug metabolism in human liver microsomes assessed as compound turnover at 10 uM after 1 hr by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID749996Inhibition of DPP4 in human Caco2 cells using H-Ala-Pro-7-amido-4-trifluoromethylcoumarin as substrate after 1 hr by fluorescence assay2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Synthetic approaches to the 2011 new drugs.
AID484491Inhibition of DPP92010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
(2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
AID1218789Inhibition of CYP2E1 in human liver microsomes assessed as chlorzoxazone 6-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID243911Ex vivo percent inhibition of Dipeptidyl peptidase IV in rat plasma after 30 min at 4 umol/kg peroral dose2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
AID1218799Inhibition of CYP2E1 in human liver microsomes assessed as chlorzoxazone 6-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218750Drug metabolism in human assessed as metabolite level in feces at 50 mg, po up to 168 hrs by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218801Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218788Inhibition of CYP2D6 in human liver microsomes assessed as bufuralol 1'-hydroxylation after 3 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1487356Inhibition of recombinant human transmembrane domain truncated DPP-4 expressed in CHO cells assessed as dissociation rate constant using Gly-Pro-pNA as substrate measured preincubated for 60 mins followed by substrate addition measured up to 40 mins2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1631908Binding affinity to human recombinant DPP4 (39 to 766 residues) assessed as association rate constant by surface plasmon resonance analysis2016Journal of medicinal chemistry, Aug-25, Volume: 59, Issue:16
Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure.
AID1487357Inhibition of recombinant human transmembrane domain truncated DPP-4 expressed in CHO cells assessed as residence time using Gly-Pro-pNA as substrate measured preincubated for 60 mins followed by substrate addition measured up to 40 mins2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID427677Inhibition of human recombinant DPP4 by fluorescence assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.
AID611367Inhibition of DPP2 up to 30 uM2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?
AID688686Selectivity ratio of IC50 for DPP9 to IC50 for human DPP42012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
AID1218775Tmax in human at 50 mg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID484493Inhibition of FAP2010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
(2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
AID1218798Inhibition of CYP2D6 in human liver microsomes assessed as bufuralol 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID688688Inhibition of human DPP2 using Lys-Ala-AMC as substrate by fluorimetric analysis2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
AID1218743Drug metabolism in human assessed as parent compound level in plasma at 50 mg, po after 1 to 8 hrs by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID240415Effective dose for inhibition of Dipeptidyl peptidase IV in prediabetic rat model after 6 hr2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
AID1218796Inhibition of CYP2C9 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218800Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1631909Binding affinity to human recombinant DPP4 (39 to 766 residues) assessed as dissociation rate constant by surface plasmon resonance analysis2016Journal of medicinal chemistry, Aug-25, Volume: 59, Issue:16
Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure.
AID238571In vitro inhibition constant against human Dipeptidyl peptidase IV2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
AID273291Inhibition of DPP82006Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the tr
AID427679Selectivity index, ratio of IC50 for human recombinant DPP7 to IC50 for human recombinant DDP82009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.
AID484489Inhibition of DPP42010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
(2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
AID688693Inhibition of DPP82012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
AID240740Inhibitory concentration against Cytochrome P450 3A42005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
AID1069728Inhibition of human recombinant DPP-4 using H-Gly-Pro-AMC as substrate after 10 mins by fluorescence assay2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1218808Induction of CYP3A4 mRNA expression in human hepatocytes assessed as testosterone 6beta-hydroxylation up to 25 uM by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1917944Inhibition of human DPP4 using Gly-Pro-AMC as substrate incubated for 30 mins by continuous fluorescent assay2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Proline based rationally designed peptide esters against dipeptidyl peptidase-4: Highly potent anti-diabetic agents.
AID688690Inhibition of DPP92012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
AID1487352Inhibition of rat DPP-4 assessed as residence time using Gly-Pro-AMC as substrate measured after 20 mins by fluorescence assay2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID429380Inhibition of DPP42009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.
AID393696Ex-vivo inhibition of DPP4 in rat plasma at 4 umol/kg after 4 hrs2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
AID1218806Induction of CYP1A2 mRNA expression in human hepatocytes assessed as phenacetin O-deethylation up to 25 uM by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218738Drug metabolism in assessed as ratio of Vmax to Km for human CYP3A5-mediated formation of 5-hydroxy saxagliptin Michaelis-Menten kinetic analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218807Induction of CYP2B6 mRNA expression in human hepatocytes assessed as bupropion hydroxylation up to 25 uM by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1473410Half life in human administered as single oral dose2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.
AID484492Inhibition of DPP22010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
(2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
AID1218777Renal clearance in human at 50 mg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1127773Inhibition of plasma DPP4 (unknown origin) after 24 hrs2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
AID1218787Inhibition of CYP2C19 in human liver microsomes assessed as (S)-mephenytoin 4'-hydroxylation after 3 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218785Inhibition of CYP2C8 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1631913Binding affinity to human recombinant DPP4 (39 to 766 residues) at 5 uM by isothermal titration calorimetry2016Journal of medicinal chemistry, Aug-25, Volume: 59, Issue:16
Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure.
AID1631910Binding affinity to human recombinant DPP4 (39 to 766 residues) assessed as residence time on target by surface plasmon resonance analysis2016Journal of medicinal chemistry, Aug-25, Volume: 59, Issue:16
Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure.
AID1218735Drug metabolism in assessed as human CYP3A4-mediated formation of 5-hydroxy saxagliptin Michaelis-Menten kinetic analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218792Inhibition of CYP1A2 in human liver microsomes assessed as phenacetin O-deethylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID302901Inhibition of human DPP42007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors.
AID427678Selectivity index, ratio of IC50 for human recombinant DPP7 to IC50 for human recombinant DDP42009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.
AID393695Ex-vivo inhibition of DPP4 in rat plasma at 4 umol/kg after 30 mins2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
AID240414Effective dose for inhibition of Dipeptidyl peptidase IV in prediabetic rat model after 4 hr2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
AID1218759Oral bioavailability in monkey2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1502449Antidiabetic activity in diet-induced obese C57BL/6 mouse assessed as reduction in plasma glucose delta AUC level at 1 mg/kg, po administered 30 mins prior to glucose challenge measured 90 mins post glucose challenge by OGTT relative to control
AID484490Inhibition of DPP82010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
(2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
AID1218761Drug excretion in human feces at 50 mg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218773Cmax in human at 50 mg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1663823Inhibition of FAP (unknown origin)2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
A cell-based fluorescent assay for FAP inhibitor discovery.
AID1218783Inhibition of CYP2A6 in human liver microsomes assessed as coumarin 7-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID611365Inhibition of DPP42011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?
AID1487391Inhibition of membrane-bound DPP-4 (unknown origin) assessed as residence time2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1218797Inhibition of CYP2C19 in human liver microsomes assessed as (S)-mephenytoin 4'-hydroxylation preincubated for 15 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1487350Inhibition of rat DPP-4 assessed as dissociation rate constant using Gly-Pro-AMC as substrate measured after 20 mins by fluorescence assay2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1218793Inhibition of CYP2A6 in human liver microsomes assessed as coumarin 7-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID237045Half life in rat2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
AID1631907Binding affinity to human recombinant DPP4 (39 to 766 residues) by surface plasmon resonance analysis2016Journal of medicinal chemistry, Aug-25, Volume: 59, Issue:16
Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure.
AID1487351Inhibition of rat DPP-4 assessed as association rate constant using Gly-Pro-AMC as substrate measured after 20 mins by fluorescence assay2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1218746Drug metabolism in human assessed as metabolite level in urine at 50 mg, po up to 168 hrs by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218755Drug metabolism assessed as human CYP3A5-mediated 5-hydroxy saxagliptin formation at 10 uM after 30 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID235984Oral bioavailability in rat2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
AID688689Inhibition of DPP4 in human plasma using Gly-Pro-AMC as substrate by fluorimetric analysis2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
AID273292Inhibition of DPP92006Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the tr
AID1218781Oral bioavailability in rat2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1218803Cytotoxicity against human hepatocytes up to 25 uM by lactate dehydrogenase assay2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID427676Selectivity index, ratio of IC50 for human recombinant DPP7 to IC50 for human recombinant DDP92009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.
AID700829Protein binding in plasma2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
The many faces of the adamantyl group in drug design.
AID1218791Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1487390Inhibition of membrane-bound DPP-4 (unknown origin) assessed as dissociation rate constant2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1127772Inhibition of DPP4 (unknown origin)2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
AID1218776Terminal half life in human at 50 mg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1345443Human dipeptidyl peptidase 4 (S9: Prolyl oligopeptidase)2009Current drug targets, Jan, Volume: 10, Issue:1
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1796747In Vitro DPP-IV Inhibition Assays from Article 10.1021/jm050261p: \\Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.\\2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (25.93)29.6817
2010's14 (51.85)24.3611
2020's6 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.62 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (22.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (77.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]